Blue Jet Healthcare Limited (BLUEJET.NS)
INR 584.5
(1.93%)
INR 584.5
(1.93%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 2.29 Billion INR | 3.52% |
| 2022 | 2.43 Billion INR | -9.46% |
| 2021 | 2.68 Billion INR | 19.43% |
| 2020 | 2.15 Billion INR | -6.34% |
| 2019 | 2.18 Billion INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 815.6 Million INR | 53.95% |
| 2024 Q1 | 442.63 Million INR | -14.41% |
| 2023 Q2 | 626.24 Million INR | 6.83% |
| 2023 Q3 | 545.82 Million INR | -12.84% |
| 2023 Q1 | 586.19 Million INR | -15.44% |
| 2023 Q4 | 530.66 Million INR | -2.78% |
| 2023 FY | - INR | 3.52% |
| 2022 Q1 | 386.18 Million INR | 0.0% |
| 2022 FY | - INR | -9.46% |
| 2022 Q4 | 693.25 Million INR | 19.03% |
| 2022 Q3 | 582.4 Million INR | -2.63% |
| 2022 Q2 | 598.11 Million INR | 54.88% |
| 2021 FY | - INR | 19.43% |
| 2020 FY | - INR | -6.34% |
| 2019 FY | - INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Biocon Limited | 41.52 Billion INR | 94.48% |
| Concord Biotech Limited | 4.65 Billion INR | 50.8% |
| Dishman Carbogen Amcis Limited | 3.07 Billion INR | 25.376% |
| Jubilant Ingrevia Limited | 4.56 Billion INR | 49.777% |
| Lyka Labs Limited | 167.58 Million INR | -1267.811% |
| Panacea Biotec Limited | -47.58 Million INR | 4917.781% |
| Piramal Pharma Limited | 13.05 Billion INR | 82.442% |
| SMS Lifesciences India Limited | 349.41 Million INR | -556.049% |
| Supriya Lifescience Limited | 1.83 Billion INR | -24.869% |
| Syngene International Limited | 10.84 Billion INR | 78.867% |
| TAKE Solutions Limited | -1.05 Billion INR | 318.14% |
| Zota Health Care Limited | 82.07 Million INR | -2693.001% |